Signal transduction

Alternative Protein Market to be worth $27.05 billion by 2027- Exclusive Report Covering Pre and Post COVID-19 Market Analysis and Forecasts by Meticulous Research®

Retrieved on: 
星期三, 三月 31, 2021
Nutrition, Protein, Branches of biology, Proteomics, Life sciences, Biotechnology, Biology, Omics, Signal transduction

A major shift in the global market's consumer behavior is increasing interest in alternative protein sources from plant-based to insects.

Key Points: 
  • A major shift in the global market's consumer behavior is increasing interest in alternative protein sources from plant-based to insects.
  • Key Findings in the Global Alternative Proteins Market Study:
    Based on stage/type, the alternative protein market is segmented into emerging alternative proteins, adolescent alternative proteins, and matured alternative proteins.
  • In 2020, the matured alternative proteins segment accounted for the largest share of the overall alternative protein market.
  • Quick Buy Alternative Protein Market Research Report: https://www.meticulousresearch.com/Checkout/34883398
    Based on application, the alternative proteins market is segmented into plant protein-based products, insect protein-based products, and microbial protein-based products.

ProMIS Neurosciences Announces Fiscal Year 2020 Results

Retrieved on: 
星期三, 三月 31, 2021
Branches of biology, Protein kinases, Receptor for activated C kinase 1, Signal transduction, Protein kinase, MTOR, Proteins, Biology

In May 2020, ProMIS announced it had identified novel antagonists against the receptor for activated protein kinase C1 (RACK1) that prevent the formation of dysfunctional protein aggregates andact torestore normal function.

Key Points: 
  • In May 2020, ProMIS announced it had identified novel antagonists against the receptor for activated protein kinase C1 (RACK1) that prevent the formation of dysfunctional protein aggregates andact torestore normal function.
  • In July 2020, the Company entered into two joint venture business arrangements (JV) with BC Neuroimmunology Lab, Inc. (BCNI).
  • In July 2020, the Company announced the voting results of the Corporation's annual meeting of shareholders held in Vancouver, BC.
  • In September 2020, ProMIS announced initiation of a program to construct and test a multivalent peptide vaccine for AD.

Antengene to Present Preclinical Data Demonstrating the Synergistic Effect of the Combination of XPO1 and mTORC1/2 Inhibition for the Treatment of Triple-Hit DLBCL at AACR Annual Meeting 2021

Retrieved on: 
星期一, 三月 22, 2021
Branches of biology, Protein complexes, Biology, Antineoplastic drugs, Signal transduction, mTORC1, MTOR, XPO1, Selinexor, HY-124798, Selective inhibitor of nuclear export

The abstract entitled "Synergistic effect of the combination of XPO1 and mTORC1/2 inhibition for the treatment of triple-hit DLBCL" now available on the AACR's website, is the first publication from the preclinical study investigating ATG-010 (XPO1 inhibitor) and ATG-008 (mTORC1/2 inhibitor).

Key Points: 
  • The abstract entitled "Synergistic effect of the combination of XPO1 and mTORC1/2 inhibition for the treatment of triple-hit DLBCL" now available on the AACR's website, is the first publication from the preclinical study investigating ATG-010 (XPO1 inhibitor) and ATG-008 (mTORC1/2 inhibitor).
  • ATG-010, also known as selinexor, is the world's first approved selective inhibitor of the nuclear export protein XPO1.
  • ATG-008 could reduce the proliferation and promote the apoptosis of tumor cells through the dual-inhibition of mTORC1 and mTORC2.
  • Other studies carried out by Antengene also showed that the dual-inhibition of XPO1 and mTOR has the effect of bolstering antitumor activities.

aTyr Pharma to Webcast Conference Call Reporting Fourth Quarter and Full Year End 2020 Financial Results

Retrieved on: 
星期二, 三月 16, 2021
Branches of biology, Protein biosynthesis, Biology, aTyr Pharma, Aminoacyl tRNA synthetase, Transfer RNA, Signal transduction

aTyr is a biotherapeutics company engaged in the discovery and development of innovative medicines based on novel biological pathways.

Key Points: 
  • aTyr is a biotherapeutics company engaged in the discovery and development of innovative medicines based on novel biological pathways.
  • aTyrs research and development efforts are concentrated on a newly discovered area of biology, the extracellular functionality and signaling pathways of tRNA synthetases.
  • aTyr has built a global intellectual property estate directed to a potential pipeline of protein compositions derived from 20 tRNA synthetase genes and their extracellular targets.
  • aTyrs primary focus is ATYR1923, a clinical-stage product candidate which binds to the Neuropilin-2 receptor and is designed to down-regulate immune engagement in inflammatory lung diseases.

Health Canada Clears Pacylex Pharmaceuticals for New Phase 1 Clinical Trial to Evaluate PCLX-001 Capsules in the Treatment of Hematologic and Solid Tumor Cancers

Retrieved on: 
星期四, 三月 11, 2021
Lymphoma, Clinical medicine, Branches of biology, Diffuse large B-cell lymphoma, Non-Hodgkin lymphoma, Medicine, Antineoplastic drugs, Signal transduction, mTOR inhibitors, SeaGen

Scientists at the University of Alberta have recently published evidence that a new drug could work in blood cancers by targeting B-cell signaling.

Key Points: 
  • Scientists at the University of Alberta have recently published evidence that a new drug could work in blood cancers by targeting B-cell signaling.
  • Pacylex is a pharmaceutical company targeting hematologic cancers with a new first-in-class therapeutic, and is headquartered in Edmonton, Alberta, Canada.
  • PCLX-001 is the lead drug in a new class of NMT inhibitors, enabling Pacylex to exploit NMTs as new clinical targets for cancer treatment.
  • Pacylex expects to begin clinical studies in Canada in the spring of 2021 in diffuse large B-cell lymphoma and solid tumors.

Surrozen Expands Board of Directors with Appointment of Mary Haak-Frendscho, Ph.D.

Retrieved on: 
星期四, 三月 11, 2021
Signal transduction, Evolutionary developmental biology, Genes, Wnt signaling pathway

SOUTH SAN FRANCISCO, Calif., March 11, 2021 (GLOBE NEWSWIRE) -- Surrozen Inc., a biotechnology company discovering and developing drug candidates to selectively modulate the Wnt pathway, today announced the addition of Mary Haak-Frendscho, Ph.D., to the Board of Directors.

Key Points: 
  • SOUTH SAN FRANCISCO, Calif., March 11, 2021 (GLOBE NEWSWIRE) -- Surrozen Inc., a biotechnology company discovering and developing drug candidates to selectively modulate the Wnt pathway, today announced the addition of Mary Haak-Frendscho, Ph.D., to the Board of Directors.
  • Dr. Haak-Frendscho brings over two decades of expertise in the discovery, translation and early development of novel therapeutics.
  • Im excited to be joining the Surrozen Board as it begins to advance novel drug candidates into clinical development and explore the full potential of Wnt biology, said Dr. Haak-Frendscho.
  • Surrozen is a biotechnology company discovering and developing drug candidates to selectively modulate the Wnt pathway.

aTyr Pharma Announces Poster Presentations at the American Association for Cancer Research (AACR) Annual Meeting

Retrieved on: 
星期四, 三月 11, 2021
Branches of biology, Biology, Cell biology, Neuropilin 2, Single-pass transmembrane proteins, aTyr Pharma, Neuropilin, Aminoacyl tRNA synthetase, Signal transduction, Cell signaling

Details of the poster presentations are as follows:

Key Points: 
  • Details of the poster presentations are as follows:
    Neuropilin-2 (NRP2) is a cell surface receptor that plays a key role in lymphatic development and in regulating inflammatory responses.
  • In many forms of cancer, high NRP2 expression is associated with worse outcomes.
  • aTyr is a biotherapeutics company engaged in the discovery and development of innovative medicines based on novel biological pathways.
  • aTyrs research and development efforts are concentrated on a newly discovered area of biology, the extracellular functionality and signaling pathways of tRNA synthetases.

Diffusion Pharmaceuticals, Inc. to Present at the H.C. Wainwright Global Life Sciences Conference

Retrieved on: 
星期四, 三月 4, 2021
Branches of biology, Signal transduction, Biology, Protein kinases, Oncology, PI3K/AKT/mTOR pathway, MTOR, Protein kinase B, Phosphoinositide 3-kinase, Diffusion Pharmaceuticals, Phosphoinositide 3-kinase inhibitor, mTOR inhibitors

Duringthepresentation, Dr. Cobuzzi willprovide an overview ofDiffusions recent corporate achievements, planned clinical trials, as well as potential milestones.

Key Points: 
  • Duringthepresentation, Dr. Cobuzzi willprovide an overview ofDiffusions recent corporate achievements, planned clinical trials, as well as potential milestones.
  • Our presentation will be available here , on the Investor Relations section of our website following the conference.
  • Diffusion Pharmaceuticals Inc. is an innovative biopharmaceutical company developing novel therapies that enhance the bodys ability to deliver oxygen to areas where it is needed most.
  • In addition to TSC, Diffusions product candidate DFN-529, a novel, allosteric PI3K/Akt/mTOR Pathway inhibitor, is in early-stage development.

2020 Full-Year Results: Major advances in NASH and significantly extended cash runway through successful IPO in the United States

Retrieved on: 
星期四, 三月 4, 2021
Hippo signaling pathway, Signal transduction

The package includes the results of two-year carcinogenicity studies in mice and rats as well as long-term toxicology studies of up to one year in monkeys.

Key Points: 
  • The package includes the results of two-year carcinogenicity studies in mice and rats as well as long-term toxicology studies of up to one year in monkeys.
  • The COVID-19 pandemic has had a large impact on patient enrollment during 2020.
  • In this context, the publication of the study results are now expected in the first half of 2022 versus 2021 as previously announced.
  • In parallel, Inventiva is in the process of selecting an oncology development candidate for its Hippo signalling pathway program.

RAPT Therapeutics to Participate in Two Investor Conferences in March

Retrieved on: 
星期三, 三月 3, 2021
Life sciences, Branches of biology, Biology, Cytokines, Biotechnology, Chemokine, Signal transduction, Inflammation, Biopharmaceutical

33rd Annual Roth Conference Featured panelist on Novel Immuno-Oncology Targets That Could Improve Clinical Outcomes panel March 15, 2021 at 2:00 pm Eastern Time.

Key Points: 
  • 33rd Annual Roth Conference Featured panelist on Novel Immuno-Oncology Targets That Could Improve Clinical Outcomes panel March 15, 2021 at 2:00 pm Eastern Time.
  • To access the live panel webcast or subsequent archived recording of the panel or company presentation, please visit the RAPT Therapeutics website at https://investors.rapt.com/events-and-presentations .
  • RAPT Therapeutics is a clinical stage immunology-based biopharmaceutical company focused on discovering, developing and commercializing oral small molecule therapies for patients with significant unmet needs in oncology and inflammatory diseases.
  • RAPT has discovered and advanced two unique drug candidates, FLX475 and RPT193, each targeting C-C motif chemokine receptor 4 (CCR4), for the treatment of cancer and inflammation, respectively.